JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Kodu・Aktsiate loetelu・Schrodinger Inc

Schrodinger Inc

Suletud

SektorTervishoid

12.22 4.18

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.54

Max

12.49

Põhinäitajad
By Trading Economics
Sissetulek	169M 136M
Müük	33M 87M
Aktsiakasum	-0.18
Kasumimarginaal	155.644
Töötajad	850
EBITDA	67M 36M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+55.45% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	118M 945M
Eelmine avamishind	8.04
Eelmine sulgemishind	12.22

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

23.27 / 26.13 Toetus ja vastupanu

Schrodinger Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. apr 2026, 23:33 UTC

Kuumad aktsiad

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28. apr 2026, 23:24 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28. apr 2026, 22:46 UTC

Tulu

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28. apr 2026, 22:37 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28. apr 2026, 22:15 UTC

Tulu

Uudisväärsed sündmused

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28. apr 2026, 23:19 UTC

Market Talk

Tulu

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28. apr 2026, 23:09 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28. apr 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees One Rate Rise to 4% in Benign Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28. apr 2026, 22:51 UTC

Tulu

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28. apr 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. apr 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28. apr 2026, 22:40 UTC

Market Talk

Uudisväärsed sündmused

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28. apr 2026, 22:32 UTC

Tulu

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28. apr 2026, 22:22 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28. apr 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28. apr 2026, 22:07 UTC

Market Talk

Uudisväärsed sündmused

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Schrodinger Inc Prognoos

Hinnasiht

By TipRanks

55.45% tõus

12 kuu keskmine prognoos

Keskmine 18.25 USD 55.45%

Kõrge 20 USD

Madal 13 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Schrodinger Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Schrodinger Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

23.27 / 26.13Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.